Decitabine (Dacogen)
Other Medications · Approved since 2006
Description
Decitabine is a DNA methyltransferase inhibitor (hypomethylating agent) that belongs to the class of epigenetic modifiers. In colorectal cancer, it is used to reverse DNA hypermethylation and restore expression of tumor suppressor genes that have been silenced by aberrant methylation. Decitabine is particularly relevant in microsatellite stable (MSS) colorectal cancer, where it may enhance immune activation when combined with immunotherapy agents like sintilimab and anti-angiogenic drugs like bevacizumab.
Mechanism of Action
Decitabine incorporates into DNA during replication and forms covalent complexes with DNA methyltransferases (DNMT1, DNMT3A, DNMT3B), leading to their depletion and subsequent DNA hypomethylation. This epigenetic reprogramming can reactivate silenced tumor suppressor genes, enhance antigen presentation, and potentially convert immunologically "cold" tumors into "hot" tumors that are more responsive to immune checkpoint inhibitors.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Dacogen |
| Category | Other Medications |
 Status | Off-label |
 Estado EMA | med_ema_approved |
 Acceso España | med_spain_hospital_use |
| Administration | IV |
| Year Approved | 2006 |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.